Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Total Liabilities (2021 - 2025)

Stoke Therapeutics has reported Total Liabilities over the past 5 years, most recently at $66.0 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 55.12% year-over-year to $66.0 million; the TTM value through Dec 2025 reached $66.0 million, up 55.12%, while the annual FY2025 figure was $66.0 million, 55.12% up from the prior year.
  • Total Liabilities for Q4 2025 was $66.0 million at Stoke Therapeutics, up from $52.2 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $77.1 million in Q2 2022 and troughed at $21.1 million in Q4 2021.
  • A 5-year average of $61.6 million and a median of $66.0 million in 2025 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: skyrocketed 237.72% in 2022 and later plummeted 38.16% in 2024.
  • Year by year, Total Liabilities stood at $21.1 million in 2021, then skyrocketed by 237.72% to $71.2 million in 2022, then dropped by 3.43% to $68.8 million in 2023, then crashed by 38.16% to $42.5 million in 2024, then soared by 55.12% to $66.0 million in 2025.
  • Business Quant data shows Total Liabilities for STOK at $66.0 million in Q4 2025, $52.2 million in Q3 2025, and $49.6 million in Q2 2025.